Gyre Therapeutics Forecasts 2026 Revenue of $100.5M-$111M
GYRE sits 31% above its 52-week low of $6.11.
Summary
Gyre Therapeutics has provided its revenue guidance for the fiscal year 2026, projecting sales to fall within the range of $100.5 million to $111 million. This new financial outlook is material for investors, offering a forward-looking perspective on the company's expected performance. While the headline does not indicate how this guidance compares to analyst expectations, it is crucial for updating financial models and assessing the company's growth trajectory, especially following its recent all-stock acquisition of Cullgen Inc. Traders will be closely monitoring any further details or commentary from management regarding the factors influencing this guidance and the integration of the acquired assets.
At the time of this announcement, GYRE was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $757.1M. The 52-week trading range was $6.11 to $12.62. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.